May 07, 2020
Syndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update
May 06, 2020
Theravance Biopharma, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update
Apr 28, 2020
Theravance Biopharma to Report First Quarter 2020 Financial Results on May 6, 2020
Apr 23, 2020
Innovent and Eli Lilly Announce NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with ALIMTA® (Pemetrexed) and Platinum as First-Line Therapy in Non-squamous NSCLC
Apr 23, 2020
Theravance Biopharma Announces First Subject Dosed in Phase 1 Study of TD-0903, in Development for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19
Mar 16, 2020
InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018 as Monotherapy and Combination Therapy in Patients with Uveal Melanoma and NRAS mutant Metastatic Melanoma in the United States
Feb 27, 2020
Trovagene Announces Fourth Quarter and Full-Year 2019 Results
Feb 24, 2020
Theravance Biopharma, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
Feb 18, 2020
Theravance Biopharma Announces Presentations at Upcoming Investor Conferences
Feb 11, 2020
Phosplatin Therapeutics Presents Positive Data from Two Phase I Studies in Metastatic Castrate-Resistant Prostate Cancer Patients at the 2020 Genitourinary Cancers Symposium
Jan 13, 2020
Tyvyt® (Sintilimab Injection) Combined with ALIMTA® (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC
Jan 12, 2020
Tyvyt (Sintilimab Injection) Combined with ALIMTA (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC
Jan 07, 2020
Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference
Dec 30, 2019
U.S. District Court Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit
Dec 03, 2019
Theravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases
Nov 14, 2019
Sierra Oncology to Present at the Jefferies 2019 London Healthcare Conference
Nov 07, 2019
Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update
Nov 06, 2019
Theravance Biopharma to Present at the 2019 Credit Suisse Healthcare Conference
Oct 29, 2019
Theravance Biopharma to Report Third Quarter 2019 Financial Results on November 5
Oct 21, 2019
Theravance Biopharma and Mylan to Present New Data on YUPELRI® (revefenacin) at the 2019 CHEST Annual Meeting